Analysis: Merck's statins turn up more muscle side effects than their rivals

Statins have long come with safety worries, but a new analysis shows that Merck & Co.'s ($MRK) products may carry more than their brethren. Pacing side effects data, Advera Health Analytics found that muscle-related side effects--which are commonly linked to the drugs--show up more often in the New Jersey giant's Zocor, Mevacor and Vytorin than in drugs in the rest of the class. More from FiercePharma

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.